Navigation Links
CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors

--By Avoiding the CNS, These Compounds May Be Free of the Side Effects Associated with Traditional Cannabinoid Compounds--

RESEARCH TRIANGLE PARK, N.C., April 1 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced issuance of a new U.S. patent covering its novel compounds that selectively target peripheral cannabinoid receptors. By avoiding the CNS, these compounds are much less likely to be associated with the side effects that have limited the utility of other cannabinoid drugs.

Developed through its discovery partnership with PharmaNess Neuroscience, CeNeRx has a portfolio of more than a dozen preclinical compounds that selectively target peripheral CB1 and CB2 cannabinoid receptors. The company is initially pursuing cannabinoid agonists for the treatment of pain (peripheral neuropathy), glaucoma and spasticity and has already demonstrated encouraging proof-of-concept results in a number of well-accepted preclinical models.

"Our cannabinoid series of compounds work via a novel, yet well-described mechanism of action, have excellent selectivity and could potentially be applied to important diseases with significant unmet need," said Barry Brand, chief executive officer of CeNeRx. "We therefore are very pleased at the issuance of this broad new U.S. patent. We believe these compounds may have the potential to provide substantial clinical benefit to patients with unmet medical needs, and to do so without the side effects that have limited the utility of cannabinoid drugs in the past."

The CeNeRx compounds were specifically designed so their activity is restricted to the peripheral nervous system, with minimal or no central nervous system activity. CNS side effects associated with traditional cannabinoid agents can be significant. For example, cannabinoid antagonists targeting the CB1 receptor, such as agents being developed to treat obesity, have been associated with such central side effects as negative mood and depression. Furthermore, cannabinoid agonists targeting CB1 receptors, including candidates being developed for pain relief, have demonstrated the potential for abuse. By acting selectively at the periphery rather than in the CNS, the CeNeRx cannabinoid compounds have the potential for good therapeutic efficacy without these adverse effects.

Mr. Brand added, "Issuance of this new patent also reinforces the ongoing value of our collaboration with our discovery partner PharmaNess, who played a central role in identifying the structure-activity relationship of this series and in running key preclinical models that validated the role of these compounds in a range of conditions including glaucoma, pain, obesity and spasticity. We look forward to continuing to collaborate with them on this and potentially other programs."

CeNeRx obtained exclusive worldwide rights to develop, manufacture and commercialize its cannabinoid compounds from PharmaNess Neuroscience in Italy. The collaboration between CeNeRx and PharmaNess also includes drug discovery efforts aimed at further expanding the cannabinoid portfolio. CeNeRx has market exclusivity for the cannabinoid series of compounds beyond 2025.

The new patent, US 7,485,730 B2 issued on February 3, 2009.

About CeNeRx BioPharma

CeNeRx is a privately held clinical stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for the treatment of major depressive disorder. RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profile. The company's CNS pipeline also includes a series of novel compounds for anxiety and depression, along with a series of selective cannabinoid compounds that have recently completed successful preclinical proof-of-concept studies for the treatment of pain, glaucoma and spasticity. More information about CeNeRx BioPharma can be found at

    GendeLLindheim BioCom Partners
    Barbara Lindheim
    212 918 4650

SOURCE CeNeRx BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CeNeRx BioPharma Completes $15 Million Series B Financing
2. DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments
3. Maryland Business, Academic and Biopharma Groups Underscore Commitment to Medical Innovation, Finding Cures and Supporting the Economy
4. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
5. Helix BioPharma Announces Q2 2009 Financial Results
6. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers
7. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
8. DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors
9. Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
10. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
11. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
Breaking Biology Technology:
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
Breaking Biology News(10 mins):